Combined Salmeterol/Fluticasone Propionate versus Fluticasone Propionate Alone in Mild Asthma
- 96 Downloads
Background and objective: Combined therapy with inhaled corticosteroids (ICSs) and long-acting β2-adrenoceptor agonists (LABAs) is the recommended approach for the treatment of patients with asthma that is uncontrolled on ICSs alone. Additional studies are needed to assess the safety and efficacy of combination treatment with ICSs and LABAs in patients with mild asthma. The aim of this study was to compare the efficacy and tolerability of once-daily salmeterol/ fluticasone propionate combination (SFC) with once-daily fluticasone propionate (FP) over a 12-week treatment period in patients with mild persistent asthma.
Methods: This was a randomized, double-blind, placebo-controlled, parallel-group, multicentre study carried out in primary care or at a hospital outpatient department and included patients 12–79 years of age with mild persistent asthma (n = 458). After a 2-week run-in period, patients were randomized to receive SFC 50 μg/100 μg (n = 149), FP 100 μg (n = 154) or placebo (n = 155) once daily in the morning for 12 weeks. The primary efficacy endpoint was patient-recorded pre-dose mean morning peak expiratory flow (PEF). Other assessments included asthma symptom scores, use of rescue medication and investigator-recorded exacerbations. Lung function was measured and assessed during clinic visits.
Results: For the primary efficacy endpoint of mean change in morning PEF, SFC achieved significantly greater increases from baseline than both placebo (difference in adjusted means 23 L/min; 95% CI 15.0, 30.3; p < 0.001) and FP (difference in adjusted means 14 L/min; 95% CI 6.3, 21.7; p < 0.001). Compared with those who received FP, patients in the SFC group demonstrated significantly greater improvements in mean evening PEF (95% CI 11.7, 28.1; p < 0.001), forced expiratory volume in 1 second (95% CI 0.093, 0.257; p < 0.001), forced expiratory flow between 25% and 75% of forced vital capacity (95% CI 0.242, 0.617; p < 0.001), the percentage of symptom-free days (95% CI 0.34, 0.87; p = 0.011), and the percentage of rescue medication-free days (95% CI 0.34, 0.90; p = 0.018). During weeks 5–12, 52% of patients in the SFC group achieved ‘well controlled’ asthma, compared with 42% and 26% of patients in the FP and placebo groups, respectively. Only one patient (receiving placebo) had a severe asthma exacerbation during the study; the frequency of adverse events was similar across the three treatment groups.
Conclusion: Once-daily SFC 50 μg/100 μg provided significantly greater improvements in lung function and in asthma symptoms than once-daily FP 100 μg alone in patients with mild persistent asthma. However, twice-daily treatment with either SFC or ICSs plus short acting β2-adrenoceptor agonists could be required to achieve guideline-defined asthma control in some patients.
KeywordsAsthma Salbutamol Fluticasone Propionate Peak Expiratory Flow Asthma Exacerbation
This study was sponsored by GlaxoSmithKline Research and Development Limited (protocol: SAS30023). Drs Jacques and Frith are employees of GlaxoSmithKline Research and Development Limited. Dr Boonsawat has received honoraria for speaking at scientific meetings and courses financed by GlaxoSmithKline and AstraZeneca. Dr Goryachkina has no conflicts of interest directly related to the content of this study.
The authors would like to thank the following investigators for their assistance with this study:
Australia: Dr M. Chia, Dr D. Freiberg, Dr M. Phillips, Dr C. Cooper, Prof. P. Thompson, Dr F. DeLooze, Dr P. Bardin, Dr C. Steinfort, Dr M. Coffey.
France: Dr D. Berman, Dr J.M. Houssel, Dr J.L. Cerutti, Dr A. Serrero, Dr F. Saint Martin, Dr F. Malaquin, Dr P. Greillier, Dr J. De Casamayor, Dr P. Bouche, Dr R. Klink, Dr F. Brugere, Dr F. Marmouz, Dr G. Somme.
Hungary: Dr Z. Gyori, Dr K. Radich, Dr H. Zibotics, Dr Z. Csontos.
Italy: Dr R. Zuin, Dr G. Cremona, Dr D. Ansalone, Dr U. Marchisio, Dr G. Pinchi, Prof. C.M. Sanguinetti, Dr M. Ronco, Dr S. Dagmar Rinnenburger, Prof. G. Bonsignore, Dr G. Pasini.
Philippines: Dr C. Yu, Dr C. Tady.
Russia: Prof. I. Smolenov, Prof. L. Ogorodova, Dr J. Popova, Prof. R. Fassakhov, Prof. V. Trofimov, Prof. M. Ilkovich, Dr T. Martynenko, Prof. I. Leshchenko.
Thailand: Dr S. Sompradeekul, Dr S. Janwityanujit, Dr A. Deesomchock, Dr H. Chantaphakul.
UK: Dr M. Garala, Dr B. Bodalia, Dr M. McCaughey, Dr S.J. Thomas.
Ukraine: Dr V. Gavrisuk, Dr Y. Feschenko, Dr V. Putintsev, Dr E. Dgiga.
- 1.Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention: 2006 [online]. Available from URL: http://www.ginasthma.org/Guidelineitem.asp?. ?11=2&12=1&intId=60 [Accessed 2007 Jan 9]Google Scholar
- 7.Global Initiative for Asthma. Global strategy for asthma management and prevention: 2004 [online]. Available from URL: http://www.ginasthma.org/Guidelineitem.asp?.11=2&12= 1&intId=987&archived=1 [Accessed 2007 Jan 9]Google Scholar
- 16.Standardization of spirometry, 1994 Update. American Thoracic Society. Am J Respir Crit Care Med 1995; 152 (3): 1107-36Google Scholar
- 17.Global Initiative for Asthma. Global Initiative for Asthma (GINA) pocket guide for asthma management and prevention. Bethesda (MD): National Institutes of Health, National Heart, Lung, and Blood Institute, 1998. Publication No. 95-3659BGoogle Scholar
- 18.National Institutes of Health. National Asthma Education and Prevention Program. Guidelines for the diagnosis and management of asthma: expert panel report 2. Bethesda (MD): National Institutes of Health, National Heart, Lung and Blood Institute, 1997. Publication No. 97-4051Google Scholar
- 20.Hollander M, Wolfe DA. Nonparametric statistical methods. London: Wiley, 1973Google Scholar
- 24.Wolfe J, Rooklin A, Grady J, et al. Comparison of once-and twice-daily dosing of fluticasone propionate 200 micrograms per day administered by diskus device in patients with asthma treated with or without inhaled corticosteroids. J Allergy Clin Immunol 2000; 105 (6 Pt 1): 1153–61PubMedCrossRefGoogle Scholar
- 26.Pauwels R, Smiltena I, Bagdonas A, et al. Seretide™ 50/100μg once daily is more effective than budesonide 400μg once daily in mild asthma: 2004 [online]. Available from URL: http://www.abstracts2view.com/ats/index.php [Accessed 2007 Jan 9]Google Scholar